The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Open accessAbstract
Importance: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective: To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. Study Selection: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results: Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. Conclusions and Relevance: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE-e4 was related to higher Alzheimer's risk in women than men between ages 55 to 70”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Carrying one APOE4 allele increases the risk of AD by 3–4 times, and carrying two alleles increases the risk by 9–15 times.168”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [168]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That is, APOE‐e4 was related to higher Alzheimer's risk in women than men between ages 55 and 70, when APOE is thought to exert its largest effects.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis found no difference between men and women in the association between APOE-e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
The cited source says what the claim attributes to it.
In the citing paper
“APOE is differentially associated with AD risk across populations [16]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“However, a meta‐analysis found no difference between men and women in the association between APOE‐e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [44]
In the citing paper
“Attempts to quantify the duration of AD should be age-specific, because age imposes the greatest risk for both dementia and mortality, and take into account APOE genotype, sex, and cerebrospinal fluid (CSF) tau levels [4, 6, 10-12].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,846
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
The normal menopause transition
McKinlay, S. M., Brambilla, D. J., & Posner, J. G. (1992) · Maturitas · doi:10.1016/0378-5122(92)90003-m · Cited by 1,112
Sex Differences in Stroke Epidemiology
Appelros, P., Stegmayr, B., & Terént, A. (2009) · Stroke · doi:10.1161/strokeaha.108.540781 · Cited by 1,076
Natural history of mild cognitive impairment in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 1,005
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 691
Late-Life Cognitive Trajectories and their Associated Lifestyle Factors
Yu, J., Feng, Q., Yu, J., Zeng, Y., & Feng, L. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191058 · Cited by 30
Inflammation in Alzheimer’s Disease: Do Sex and APOE Matter?
Duarte‐Guterman, P., Initiative, O. B. O. T. A. D. N., Albert, A., Inkster, A. M., Barha, C. K., & Galea, L. A. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200982 · Cited by 31
Christensen, A., & Pike, C. J. (2018) · The FASEB Journal · doi:10.1096/fj.201801756r · Cited by 31
Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer's disease
Liu, L., & Caselli, R. J. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.006 · Cited by 29
Fernández, A., Cuesta, P., Marcos, A., Montenegro-Peña, M., Yus, M., Rodríguez‐Rojo, I. C., Bruña, R., Maestú, F., & López, M. E. (2023) · GeroScience · doi:10.1007/s11357-023-01020-z · Cited by 29
A comprehensive analysis of APOE genotype effects on human brain structure in the UK Biobank
Heise, V., Offer, A. R., Whiteley, W. N., Mackay, C. E., Armitage, J., & Parish, S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02848-5 · Cited by 31
Cheng, C.-K., Tsao, Y., Su, Y., Sung, F., Tai, H.-C., & Kung, W. (2018) · Behavioural Neurology · doi:10.1155/2018/8312346 · Cited by 29
APOE effects on cognition from childhood to adolescence
Reynolds, C. A., Smolen, A., Corley, R. P., Muñoz, E., Friedman, N. P., Rhee, S. H., Stallings, M. C., DeFries, J. C., & Wadsworth, S. J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.011 · Cited by 30
Sex differences in risk of Alzheimer's disease in adults with Down syndrome
Lai, F., Mhatre, P. G., Yang, Y., Wang, M., Schupf, N., & Rosas, H. D. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12084 · Cited by 29
Rabaneda‐Bueno, R., Mena‐Montes, B., Torres‐Castro, S., Torres‐Carrillo, N., & Torres-Carrillo, N. M. (2021) · Genes · doi:10.3390/genes12121959 · Cited by 30
APOE ε4 is associated with decreased synaptic density in cognitively impaired participants
He, K., Li, B., Wang, J., Wang, Y., You, Z., Chen, X., Chen, H., Li, J., Huang, Q., Guo, Q., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13775 · Cited by 29
Self-citationMuza, P. M., Bachmeier, C. J., Mouzon, B., Algamal, M., Rafi, N. G., Lungmus, C., Abdullah, L. I., Evans, J. E., Ferguson, S., MULLAN, M. J., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.049 · Cited by 28
Forcano, L., Fauria, K., Soldevila‐Domenech, N., Minguillón, C., Lorenzo, T., Cuenca‐Royo, A., Menezes‐Cabral, S., Pizarro, N., Boronat, A., Molinuevo, J. L., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12155 · Cited by 30
Ourry, V., Binette, A. P., St‐Onge, F., Strikwerda‐Brown, C., Chagnot, A., Poirier, J., Breitner, J. C. S., Arenaza‐Urquijo, E. M., Rabin, J. S., Buckley, R. F., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.09.003 · Cited by 30
Fish, n-3 fatty acids, cognition and dementia risk: not just a fishy tale
Saleh, R. N. M., & Minihane, A. M. (2021) · Proceedings of The Nutrition Society · doi:10.1017/s0029665121003700 · Cited by 28
Vila‐Castelar, C., Tariot, P. N., Sink, K. M., Clayton, D., Langbaum, J. B. S., Thomas, R. G., Chen, Y., Su, Y., Chen, K., Hu, N., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12552 · Cited by 27
Self-citationSaunders, T. S., Jenkins, N. D., Blennow, K., Ritchie, C. W., & Terrera, G. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104241 · Cited by 28
Zhou, C., Dong, C., Xie, Z., Hao, W., Fu, C., Sun, H., & Zhu, D. (2023) · Biology of Sex Differences · doi:10.1186/s13293-023-00491-1 · Cited by 29
Functional variants identify sex-specific genes and pathways in Alzheimer’s Disease
Bourquard, T., Lee, K. D., Al‐Ramahi, I., Pham, M., Shapiro, D., Lagisetty, Y., Soleimani, S., Mota, S., Wilhelm, K. O., Samieinasab, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38374-z · Cited by 32
Steroid hormones: risk and resilience in women’s Alzheimer disease
Calvo, N., & Einstein, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1159435 · Cited by 27
Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries
Xu, X., Kwon, J., Yan, R., Apio, C., Song, S. C., Heo, G., Yang, Q., Timsina, J., Liu, M., Budde, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0562 · Cited by 30
Self-citationGlobal genetic diversity of human apolipoproteins and effects on cardiovascular disease risk
Zhou, Y., Mägi, R., Milani, L. A., & Lauschke, V. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p086710 · Cited by 28
Yan, S., Zheng, C., Paranjpe, M. D., Li, J., Benzinger, T. L. S., Lu, J., & Zhou, Y. (2020) · Theranostics · doi:10.7150/thno.48522 · Cited by 27
Similar Genetic Architecture of Alzheimer’s Disease and Differential APOE Effect Between Sexes
Wang, H., Lo, M.-T., Rosenthal, S. B., Makowski, C., Andreassen, O. A., Salem, R. M., McEvoy, L. K., Fiecas, M. J. A., & Chen, C. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.674318 · Cited by 27
Demby, T. C., Rodriguez, O. C., McCarthy, C. W., Lee, Y., Albanese, C., Mandelblatt, J. S., & Rebeck, G. W. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112534 · Cited by 26
Sex hormones, vascular factors and cognition
Szoeke, C. E. I., Downie, S., Parker, A. F., & Phillips, S. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100927 · Cited by 26
Bonkhoff, A. K., Coughlan, G., Perosa, V., Alhadid, K., Schirmer, M. D., Regenhardt, R. W., van Veluw, S. J., Buckley, R. F., Fox, M., & Rost, N. S. (2025) · Science Advances · doi:10.1126/sciadv.adt9243 · Cited by 26
Averill, L. A., Abdallah, C. G., Levey, D. F., Han, S., Harpaz‐Rotem, I., Kranzler, H. R., Southwick, S. M., Krystal, J. H., Gelernter, J. E., & Pietrzak, R. H. (2019) · Depression and Anxiety · doi:10.1002/da.22912 · Cited by 25
Polygenic resilience scores capture protective genetic effects for Alzheimer’s disease
Hou, J., Hess, J., Armstrong, N. J., Bis, J. C., Grenier‐Boley, B., Karlsson, I., Leonenko, G., Numbers, K. T., O’Brien, E. K., Shadrin, A. A., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02055-0 · Cited by 26
Meiner, Z., Ayers, E. I., Bennett, D. A., Wang, C., & Verghese, J. (2021) · European Journal of Neurology · doi:10.1111/ene.14841 · Cited by 25
Sex differences in a murine model of Cerebral Amyloid Angiopathy
Maniskas, M. E., Mack, A. F., Morales‐Scheihing, D., Finger, C. E., Zhu, L., Paulter, R., Urayama, A., McCullough, L. D., & Manwani, B. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100260 · Cited by 26
Auerbach, B. J., Hu, J., Reilly, M. P., & Li, M. (2021) · Genome Research · doi:10.1101/gr.275430.121 · Cited by 28
Sayfullaeva, J., McLoughlin, J., & Kwakowsky, A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240899 · Cited by 26
Sex hormones and cognition in aging
Gurvich, C., Le, J., Thomas, N., Thomas, E. H. X., & Kulkarni, J. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.020 · Cited by 25
Reproductive factors and cognitive impairment in natural menopausal women: A cross-sectional study
Xi, H., Gan, J., Liu, S., Wang, F., Chen, Z., Wang, X., Shi, Z., & Ji, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.893901 · Cited by 24
Karim, R., Koç, M., Rettberg, J. R., Hodis, H. N., Henderson, V. W., John, J. A. S., Allayee, H., Brinton, R. D., & Mack, W. J. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001160 · Cited by 24
Başgöz, B. B. (2020) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2020.3803 · Cited by 24
Impacts of Iron Metabolism Dysregulation on Alzheimer’s Disease
Jouini, N., Saied, Z., Sassi, S. B., Nebli, F., Messaoud, T. B., Hentati, F., & Belal, S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201250 · Cited by 25
Choi, Y. Y., Lee, J. J., Choi, K. Y., Seo, E. H., Choo, I. H., Kim, H., Song, M., Choi, S., Cho, S. H., Kim, B. C., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00233 · Cited by 24
Reduced rapid eye movement sleep in late middle-aged and older apolipoprotein E ɛ 4 allele carriers
André, C., Martineau‐Dussault, M., Baril, A., Marchi, N. A., Daneault, V., Lorrain, D., Hudon, C., Bastien, C., Petit, D., Thompson, C., et al. (2024) · SLEEP · doi:10.1093/sleep/zsae094 · Cited by 24
Flynn, C. M., Omoluabi, T., Janes, A. M., Rodgers, E. J., Torraville, S. E., Negandhi, B. L., Nobel, T. E., Mayengbam, S., & Yuan, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01674-1 · Cited by 26
Sex differences and the role of estrogens in the immunological underpinnings of Alzheimer's disease
Price, B. R., Walker, K. A., Eissman, J. M., Suryadevara, V., Sime, L. N., Hohman, T. J., & Gordon, M. N. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70139 · Cited by 25
Dulka, B. N., Trask, S., & Helmstetter, F. J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.656944 · Cited by 23
Cacciaglia, R., Salvadó, G., Molinuevo, J. L., Shekari, M., Falcón, C., Operto, G., Suárez‐Calvet, M., Milà‐Alomà, M., Sala, A., Rodriguez‐Vieitez, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01436-7 · Cited by 23
Ali, M., Sung, Y. J., Wang, F., Fernández, M. V., Morris, J. C., Fagan, A. M., Blennow, K., Zetterberg, H., Heslegrave, A., Johansson, P., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267298 · Cited by 23
Apolipoprotein E Recognizes Alzheimer's Disease Associated 3‐O Sulfation of Heparan Sulfate
Mah, D., Zhu, Y., Su, G., Zhao, J., Canning, A., Gibson, J. M., Song, X., Stancanelli, E., Xu, Y., Zhang, F., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202212636 · Cited by 26
Self-citationMenopause and Alzheimer’s disease susceptibility: Exploring the potential mechanisms
Breeze, B., Connell, E., Wileman, T., Müller, M. M., Vauzour, D., & Pontifex, M. G. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149170 · Cited by 22
Calvo, N., McFall, G. P., Ramana, S., Galper, M., Fuller‐Thomson, E., Dixon, R. A., & Einstein, G. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240646 · Cited by 22
Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease
Patra, K., Giannisis, A., Edlund, A. K., Sando, S. B., Lauridsen, C., Berge, G., Grøntvedt, G. R., Bråthen, G., White, L. R., & Nielsen, H. M. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190175 · Cited by 22
Sex differences in associations between APOE ε2 and longitudinal cognitive decline
Alexander, M. W., Xiong, L. Y., Wong, Y. Y., Buckley, R. F., Swardfager, W., Masellis, M., Lim, A. S. P., Nichols, E., Joie, R. L., Casaletto, K. B., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13036 · Cited by 25
Self-citationSex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume
Caldwell, J., Berg, J.-L., Shan, G., Cummings, J. L., Banks, S. J., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180028 · Cited by 22
Yassine, H. N., Anderson, A., Brinton, R. D., Carmichael, O. T., Espeland, M. A., Hoscheidt, S. M., Hugenschmidt, C. E., Keller, J. N., Peters, A. L., & Pi-Sunyer, X. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.020 · Cited by 22
Lee, M., Hughes, T. M., George, K. M., Griswold, M. E., Sedaghat, S., Simino, J. M., & Lutsey, P. L. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab299 · Cited by 22
Caldwell, J., Kinney, J. W., Ritter, A. R., Salazar, A., Wong, C. G., Cordes, D., & Slavich, G. M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.12.001 · Cited by 23
Sex differences in early‐onset Alzheimer's disease
Contador, J., Pérez‐Millan, A., Guillén, N., Sarto, J., Tort‐Merino, A., Balasa, M., Falgàs, N., Castellví, M., Borrego‐Écija, S., Juncà‐Parella, J., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15531 · Cited by 21
Ji, W., An, K., Wang, C., & Wang, S. (2022) · Hereditas · doi:10.1186/s41065-022-00252-x · Cited by 23
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood
Pettigrew, C. A., Soldan, A., Wang, J., Wang, M., Greenberg, B., Albert, M., & Moghekar, A. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12374 · Cited by 21
Self-citationCelis, K., Moreno, M. D. M. M., Rajabli, F., Whitehead, P. L., Hamilton‐Nelson, K. L., Dykxhoorn, D. M., Nuytemans, K., Wang, L., Flanagan, M. E., Weıntraub, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13075 · Cited by 23
Self-citationPandey, R. S., Arnold, M., Batra, R., Krumsiek, J., Kotredes, K. P., Garceau, D. T., Williams, H. M., Sasner, M., Howell, G. R., Kaddurah‐Daouk, R., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13851 · Cited by 22
Ma, X., Wei, J., Congdon, N. G., Li, Y., Shi, L., & Zhang, D. “. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211006467 · Cited by 21
Pitchika, A., Markus, M. R. P., Schipf, S., Teumer, A., der Auwera, S. V., Nauck, M. A., Dörr, M., Felix, S. B., Grabe, H. J., Völzke, H., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109778 · Cited by 21
Reas, E. T., Triebswetter, C., Banks, S. J., & McEvoy, L. K. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01380-w · Cited by 21
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
BackgroundThe Spectrum of Genetic Risk in Alzheimer Disease
Karagas, N. E., Young, J. E., Blue, E., & Jayadev, S. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200224 · Cited by 22
Lindbergh, C. A., Hillblom Aging Network, Casaletto, K. B., Staffaroni, A. M., Joie, R. L., Iaccarino, L., Edwards, L., Tsoy, E., Elahi, F. M., Walters, S. M., et al. (2020) · Neuropsychology · doi:10.1037/neu0000696 · Cited by 21
Genetic profiles of familial late-onset Alzheimer's disease in China: The Shanghai FLOAD study
Xie, X., Zhao, Q., Huang, Q., Dammer, E. B., Chen, S., Ren, R., & Wang, G. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.05.001 · Cited by 20
Sauty, B., & Durrleman, S. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1161527 · Cited by 24
Pearse, R. V., & Young‐Pearse, T. L. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146352 · Cited by 22
Leoutsakos, J., Wise, E. A., Lyketsos, C. G., & Smith, G. S. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5203 · Cited by 22
Vonk, J. M. J., Rentería, M. A., Medina, V., Pericak‐Vance, M. A., Byrd, G. S., Haines, J. L., Brickman, A. M., & Manly, J. J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190415 · Cited by 21
Key biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies
Jamal, R., Shaikh, M. A., Taleuzzaman, M., Haque, Z., Albratty, M., Alam, M. S., Makeen, H. A., Zoghebi, K. A., & Saleh, S. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330500 · Cited by 19
CSF biomarkers in Olmsted County
Harten, A. V. V., Wiste, H., Weigand, S., Mielke, M., Kremers, W., Eichenlaub, U., Batrla-Utermann, R., Dyer, R. B., Algeciras-Schimnich, A., Knopman, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009874 · Cited by 8
Lutshumba, J., Wilcock, D. M., Monson, N. L., & Stowe, A. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106202 · Cited by 20
APOE genotype and sex modulate Alzheimer’s disease pathology in aged EFAD transgenic mice
Balu, D., Valencia‐Olvera, A. C., Islam, Z., Mielczarek, C., Hansen, A. L., Ramos, T. M. P., York, J. M., LaDu, M. J., & Tai, L. M. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1279343 · Cited by 20
Minding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer’s Disease
Reed-Geaghan, E. G., & Keller-Norrell, P. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417377 · Cited by 19
Lee, B. H., Cevizci, M., Lieblich, S. E., Ibrahim, M., Wen, Y., Eid, R. S., Lamers, Y., Duarte‐Guterman, P., & Galea, L. A. M. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.05.019 · Cited by 21
Shen, S., Zhou, W., Chen, X., & Zhang, J. (2019) · European Journal of Neurology · doi:10.1111/ene.13987 · Cited by 18
Imaging the aging brain: study design and baseline findings of the SENIOR cohort
Haeger, A., Mangin, J., Vignaud, A., Poupon, C., Grigis, A., Boumezbeur, F., Frouin, V., Deverre, J.-R., Sarazin, M., Hertz‐Pannier, L., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00642-1 · Cited by 21
Hypertension and Hypercholesterolemia Modify Dementia Risk in Relation to APOE ɛ4 Status
Pillai, J. A., Kou, L., Bena, J., Penn, L., & Leverenz, J. B. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201609 · Cited by 20
Shang, X., Roccati, E., Zhu, Z., Kiburg, K., Wang, W., Huang, Y., Zhang, X., Zhang, X., Liu, J., Tang, S., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01140-2 · Cited by 18
“It has been reported that the risk for Alzheimer’s disease associated with APOE Ɛ4/Ɛ4 was higher in men than in women [32].”
BackgroundWang, X., & Cao, Y. (2025) · Biomolecules · doi:10.3390/biom15020188 · Cited by 18
Advances in the genetics and pathology of Lewy body dementia
Scholz, S. W., Okubadejo, N. U., Prakash, P., Liddelow, S. A., Ryten, M., & Halliday, G. M. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00363-1 · Cited by 20
Sex‐specific biomarkers in Alzheimer's disease progression: Framingham Heart Study
Liu, C., Li, Y., Nwosu, A., Ang, T. F. A., Liu, Y., Devine, S., Au, R., & Doraiswamy, P. M. (2022) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12369 · Cited by 19
Self-citationAD and non‐AD mediators of the pathway between the APOE genotype and cognition
Nichols, E., Brickman, A. M., Casaletto, K. B., Dams-O’Connor, K., George, K. M., Kumar, R. G., Palta, P., Rabin, J. S., Satizábal, C. L., Schneider, J. A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12885 · Cited by 18
Self-citationSinghaarachchi, P. H., Antal, P., Calon, F., Culmsee, C., Delpech, J.-C., Feldotto, M., Geertsema, J., Hoeksema, E. E., Kőrösi, A., Layé, S., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105724 · Cited by 20
Espeland, M. A., Hayden, K. M., Lockhart, S. N., Yassine, H. N., Hoscheidt, S. M., Yaşar, S., Luchsinger, J. A., Neiberg, R. H., Brinton, R. D., & Carmichael, O. T. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz090 · Cited by 18
The Association between Sex and Risk of Alzheimer’s Disease in Adults with Down Syndrome
Mhatre, P. G., Lee, J. H., Pang, D. I., Zigman, W. B., Tycko, B., Krinsky‐McHale, S. J., Yang, Y., Silverman, W. P., & Schupf, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132966 · Cited by 18
Jiang, L., Lin, H., Initiative, A. D. N., & Chen, Y. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134824 · Cited by 17
Self-citationEpigenetic Mechanisms Underlying Sex Differences in Neurodegenerative Diseases
Stoccoro, A. (2025) · Biology · doi:10.3390/biology14010098 · Cited by 18
Impact of APOE , Klotho, and sex on cognitive decline with aging
Shibata, K., Chen, C., Tai, X. Y., Manohar, S., & Husain, M. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2416042122 · Cited by 18
Francesco, S. D., Galluzzi, S., Vanacore, N., Festari, C., Rossini, P. M., Cappa, S. F., Frisoni, G. B., & Redolfi, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656808 · Cited by 17
Self-citationLiew, T. M. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221079217 · Cited by 18
Differential association of cerebral blood flow and anisocytosis in APOE ε4 carriers at midlife
Dounavi, M., Mak, E., Swann, P., Low, A., Terrera, G. M., McKeever, A., Pope, M., Williams, G. B., Wells, K., LAWLOR, B. A., et al. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231173587 · Cited by 17
Toga, A. W., Phatak, M., Pappas, I., Thompson, S., McHugh, C., Clement, M. H. S., Bauermeister, S., Maruyama, T., & Gallacher, J. (2023) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2023.1175689 · Cited by 17
Self-citationAmbikairajah, A., Khondoker, M. R., Morris, E., de Lange, A. G., Saleh, R. N. M., Minihane, A. M., & Hornberger, M. (2024) · Human Brain Mapping · doi:10.1002/hbm.26612 · Cited by 17
Miramontes, S., Serras, C. P., Woldemariam, S. R., Khan, U., Li, Y., Tang, A., Tsoy, E., Oskotsky, T., & Sirota, M. (2024) · npj Women s Health · doi:10.1038/s44294-024-00021-3 · Cited by 19
Pramanik, S., Harini Devi, M., Chakrabarty, S., Paylar, B., Pradhan, A., Thaker, M., Ayyadhury, S., Manavalan, A., Olsson, P., Pramanik, G., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105834 · Cited by 18
Peterson, A. J., Sathe, A., Zaras, D., Yang, Y., Durant, A., Deters, K., Shashikumar, N., Pechman, K. R., Kim, M. E., Gao, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14343 · Cited by 18
Self-citationZhu, L., Shu, H., Liu, D., Guo, Q., Wang, Z., & Zhang, Z. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00289 · Cited by 19
Durai, P., Beeraka, N. M., Vikram, P. R. H., Krishnan, P., Gudur, P., Raghavendra, N. M., & Ravanappa, P. K. B. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211109141330 · Cited by 17
Régy, M., Dugravot, A., Sabia, S., Fayossé, A., Mangin, J., Marie Chupin, A., Fischer, C., Bouteloup, V., Dufouil, C., Chêne, G., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118966 · Cited by 23
Metadata
- Authors
- Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S. P., Redolfi, A., Orlandi, D., Frisoni, G. B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S. C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., & Toga, A. W.
- Affiliations
- University of Southern California (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Critical Path Institute (US)
- Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Geneva (CH)
- Boston University (US)
- Fundació ACE (ES)
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- University of Wisconsin–Madison (US)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Corresponding author
- Toga, Arthur W.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-01
- Volume
- 74
- Issue
- 10
- Pages
- 1178
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5759346
- OpenAlex
- W2745657465
- Cited by
- 674
- References
- 74
- Citations by year
- 2026: 74 · 2025: 81 · 2024: 74 · 2023: 93 · 2022: 78 · 2021: 96 · 2020: 69 · 2019: 67 · 2018: 37 · 2017: 3
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000130, 5u01ag024904-10, n01hc25195-41-0-1, UL1TR001855)
- U.S. Food and Drug Administration (U18FD005320)
- National Institute on Aging (U01-AG-024904, P30AG010129, P30AG010133, P30AG028383, P30AG012300, P50AG005133, U01AG016976, P50AG005131, P50AG005138, P50AG016570, P30AG010124, P50AG016573, RF1AG027161, P50AG047366, P30AG008017, P30AG010161, R01AG033040, P30AG008051, P50AG008702, R01AG016495, P50AG033514, P30AG035982, P50AG005681, P50AG005142, P50AG047270, P30AG019610, P50AG005146, P01AG003991, RF1AG054617, P30AG013846, P50AG005136, P50AG005134, P30AG013854, P50AG025688, P50AG047266, R01AG008122, R01AG027161, U24AG041689, U19AG024904, P01AG026276, P50AG023501, P50AG016574)
- National Heart, Lung, and Blood Institute (N01-HC-025195)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- National Institute of Biomedical Imaging and Bioengineering (U54EB020406, P41EB015922)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- Alzheimer's disease, apolipoprotein E, APOE ε4, APOE ε2, sex differences, mild cognitive impairment, genetic risk factors
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Female, Humans, Male, Middle Aged, Risk Factors, Sex Characteristics, Logistic Models, Case-Control Studies, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
